This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment? Ketamine treatment for depression may be one of the biggest leaps forward in mental healthcare in decades.
As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.
Before we dive into the research, here’s the lowdown: Important takeaway points on cannabis and cancer Your situation is unique. Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. 1 So can cannabis cure cancer?
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
Researchers from Temple University sought to find out how recreational marijuana legalization in Washington and Colorado influenced adolescent treatment admissions for cannabis. MARIJUANA LEGALIZATION & YOUTH DRUG TREATMENT ADMISSIONS. Researchers Jeremy Mennis and Gerald J.
Clinical trials are medical research projects involving human participants. The main goals with conducting clinical studies, which could include observational studies or clinical trials, are to explore the causes of a disease or its symptoms, test a treatment, and learn how a certain behaviour affects patients’ health.
What will unrestricted access to Medicinal Cannabis look like in Australia? A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. kg of CBD and 163.7
This is according to a group of researchers from the University of New Mexico (UNM) , who recently teamed up with the creators of the Releaf App to investigate the true link between cannabis use and energy levels. The sessions were logged by a total of 1,224 people who had access to the app. Promising News for Endless Patients.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
The findings of a new study into cannabis use disorder (CUD) among veterans have been released by a team of researchers from Pennsylvania’s Center of Excellence in Substance Addiction Treatment and Education at the Corporal Michael J. Crescenz VA Medical Center. Their hypothesis was published in the American Journal of Psychiatry.
Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications. The progress Beckley Psytech has made in attracting exceptional talent to the team and advancing our ambitious clinical development programmes over the past two years has been tremendously exciting.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
“There were times when I was told you couldn’t even use ‘cannabis’ and ‘research’ in the same sentence,” he recalled. which is conducting millions of dollars worth of research on the use of cannabis to treat conditions including anxiety, insomnia and pain. The federal government is investing in marijuana research too.
million in gifts in support of several causes, including the promotion of arts, Lyme and tick-borne disease research, protection of the environment, and, in this case, psychedelics research. to advance scientific research into the potential therapeutic benefits of psychedelics for mental health and well-being.
NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.
Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Unfortunately, tobacco is easy to access and addiction is hard to curb.
Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
Artificial intelligence is a smarter, faster, and more effective pathway to drug development. With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.
This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies.
This collaboration is intended to include research into COMP360 psilocybin therapy and other novel therapies that may be developed by COMPASS in areas of unmet need such as depression, post-traumatic stress disorder (PTSD) and anorexia. George Goldsmith, CEO and Co?founder,
Note: Veriheal does not support illegally consuming therapeutic substances such as Iboga but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Is There Any Research on Iboga and Its Medicinal Properties?
Traditional treatments, while helpful to some extent, often come with limitations and side effects that can further burden individuals already dealing with a debilitating disease. Medical marijuana has emerged as a promising alternative treatment option for managing symptoms associated with MS.
At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value. As a result, medical and scientific research has been highly constrained for many decades. Exponential Increase in Cannabis Research: Trends.
The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors.
While at home in Australia, the Medical Cannabis industry is still working hard to gather more evidence-based research to substantiate treatment assertions, relevant studies are already occurring overseas. It’s heartening to see the release of more and more evidence-based global research surrounding Medical Cannabis-based treatment.
We want to be an industry leader in preventing negative side effects during treatment and believe this can be of benefit to the entire industry.” Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. Media Inquiries: Gabe Rodriguez. Gabe@Ehave.com.
Cannabis has been identified as an effective alternative treatment for some gastrointestinal disorders…but does that include IBD and IBS? . Diet is used as the primary treatment. . Dronabinol is commonly used as a treatment in cancer patients due to the fact that it can decrease gut transit and increase colon compliance.
A team of researchers at Tel Aviv University in Tel Aviv, Israel, led by Ph.D. The cannabis compound cannabidivarin (CBDV) has already been found to be a promising treatment for ASD, particularly in terms of repetitive behaviors, irritability, social functioning, and inflammation. About the Study: Autism and Cannabis.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
As medical research advances, scientists are exploring how cannabis compounds offers new possibilities for managing these chronic autoimmune conditions. More and more cannabis researchers are entering the scene to uncover how cannabis works to decrease autoimmune disorders symptoms, not just the pain and inflammation that comes from them.
The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”
At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. The company is scaling its proprietary research and development methods in order to become one of the first to produce and bring to market psilocybin-based treatments.
is a pioneering Psychedelic Healthcare Innovation & Life Sciences Company in early stage development of Psilocybin (“Magic Mushroom”) based drugs and therapies proudly announces t he Filing of U. HENDERSON, Nev. , Sept. 9, 2021 /PRNewswire/ — PsiloThera, Inc. ” The U.S.
Though the distinction between these terms may seem trivial at first glance, it is in fact crucial for cannabis research, and therefore also for consumers and regulators as well. Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using.
As legalization opens new pathways for cannabis research, studies continue to expand the growing list of marijuana’s medical benefits. According to Eric Brown , lead researcher in the study at McMaster University: These findings suggest real therapeutic potential for cannabinoids as antibiotics. Is marijuana the next antibiotic?
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.
The study is the first of its kind and will be conducted within Swinburne’s Drugs and Driving Research unit, which is led by Professor Downey. ‘We We are grateful for this grant, and especially for the opportunity to further our research in this space,’ says Professor Downey. ‘It Medicinal Cannabis Research Collaboration (MCRC).
Depression and addiction continue to impact millions of lives worldwide, making the search for effective treatments crucial. In a recent 2023 study , scientists have developed two promising drug candidates for treating these conditions, drawing inspiration from a traditional African psychedelic plant medicine called ibogaine.
For those unfamiliar, GB Sciences is a technology company that merges plant biology, cultivation, and post-production processes in order to optimize safe, consistent medical cannabis treatment. They describe their goal as “marrying cutting edge cannabis cultivation with biopharmaceutical research and development.”
Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content